Purpose Glutamate is the most abundant neurotransmitter in the brain, and proton magnetic resonance spectroscopy (MRS) allows quantification of glutamate-related metabolites (glutamate/glutamine complex; Glx). In previous findings, Glx has been lower in several brain regions of patients with major depressive disorder than in those of healthy controls. However, the physiologic and characteristic distribution of Glx in the same individual remains unclear. We attempted to clarify which brain regions reflect changes associated with depression. Material and method We measured Glx in 12 patients with depression and 12 healthy controls matched for age and sex in three brain regions (left amygdala, left anterior cingulate cortex, and left dorsolateral prefrontal cortex), and then compared the physiologic and characteristic distribution of Glx between the two groups. Results In comparisons of the distributions, Glx was significantly higher in the amygdala than in other regions. Glx tended to be lower among the patients than the controls, although no significant differences were present between the groups. We could not detect the changes expected from major depressive disorder (reduced Glx) in the amygdala, which regulates emotions and shows higher concentrations of Glx than other regions. Conclusion Previous studies have suggested that the concentration of Glx decreases with age, and this might have influenced our results regarding changes with major depressive disorder. In addition, we could not clarify whether medications affected the patient condition, because treatment for depression increased Glx in previous studies. Further MRS studies are needed to clarify Glx distributions in the specific diagnosis of depression.
Introduction
Major depressive disorder (MDD) is one of the most common psychiatric disorders in the general population, and the prevalence appears to be increasing 1)2) . Although the pathophysiology of MDD has not been clarified, a growing body of evidence has shown contributions from glutamate, the most abundant excitatory neurotransmitter in the brain, and the glutamatergic system 3) . Recent advances in proton magnetic resonance spectroscopy ( 1 H-MRS) have allowed direct, non-invasive, in vivo measurement of brain metabolites, including glutamate-related metabolites, particularly glutamate and glutamine (collec-tively termed Glx). The sophistication and utility of 1 H-MRS studies have been improving over recent years, and this approach can now be used to examine the relation between glutamatergic function and diagnosis, clinical state, treatment response, and specific emotional/cognitive interventions 3) . In recent years, quantification studies of brain Glx in patients with MDD using 1 H-MRS have been carried out that showed significant reductions in Glx in several brain regions 3)4) . Such regions include the anterior cingulate cortex (ACC) 5)6) , dorsolateral prefrontal cortex (DLPFC) 7) , dorsomedial prefrontal cortex 8) , amygdala 7) , and hippocampus 9) , areas also thought to be associated with mood regulation and the pathophysio- According to our review of prior studies, the region showing the greatest reduction in Glx has not been investigated in individual patients. We therefore aimed to investigate the physiologic and characteristic distribution of Glx in each region within individuals, and to compare differences between healthy controls and patients with MDD. We measured brain Glx in patients with MDD and in the same number of controls using 3-T 1 H-MRS focused on three regions (left amygdala, ACC and DLPFC). By comparing the results, we tried to clarify the most appropriate regions for measuring Glx in patients with MDD, and examined whether disease severity could be assessed in each region.
Materials and methods

Subjects
Individuals who met Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria for current major depressive episode and for MDD and also had a Hamilton Depression Rating Scale (HAM-D) score >7 (n=12; 7 women; age range, 47-82 years; mean age, 62.6 ± 11.2 years) participated as members of the MDD group ( Table 1) . HAM-D is a tool for evaluating depression that scores the severity of symptoms and delineates 5 classes: normal, score 0-7; mild, 8-13; moderate, 14-18; severe, 19-22; and most severe, ≥23. The mean (± standard deviation) HAM-D score in the patient group was 22.9 ± 5.3, corresponding to the "severe state" ( Table 1) . For comparison, the same number of healthy volunteers (n=12; 7 women; age range, 42-80 years; mean age, 60.8 ± 9.6 years) who were confirmed as having no obvious psychiatric symptoms of psychiatric dis-ease before participation were included as members of the control group. Age and sexes of the healthy volunteers were matched to those of the patients. Mean HAM-D score for the control group was estimated to be less than 7, corresponding to the "normal state", as no obvious psychiatric symptoms were present. All patients were hospitalized for the treatment of MDD prior to registration. The patient group was examined by MRS within almost one week after admission. MRS examinations of the healthy volunteers, were conducted at any time after consent was obtained. Just before the first MRS, a magnetic resonance imaging (MRI) examination was conducted in all subjects to confirm the absence of organic disease. When MRS was performed, depressive symptoms and the HAM-D score were evaluated by psychiatrists. Psychiatric diagnoses were established using an unstructured clinical interview by a psychiatrist and via a structured interview using the Structured Clinical Interview for the DSM-IV. All patients were receiving oral pharmacotherapy including antidepressants, hypnotics, minor tranquilizers, and major tranquilizers. These agents are listed in Table 1 . Participants were entered into the study after they received a full explanation of the purpose of the study and provided written informed consent for participation. The study procedures were approved by the ethics committee at St. Marianna University School of Medicine, Japan (approval number 3026).
MRS
Participants were examined with a 3-T MRI scanner (Ingenia 3.0T; PHILIPS, Amsterdam, the Netherlands) using single-voxel, point-resolved spectroscopy mode. Prior to MRS examination, T1- weighted brain images in axial, coronal, and sagittal views were acquired for voxel planning and confirmation of the absence of any other obvious disease.
For the purpose of comparing spectra between different regions in the brain, three region-of-interest (ROI) voxels were placed based on previous imaging 7)10)11) and histopathological studies referring to appropriate areas to accurately measure amounts of Glx -the left amygdala voxel, the left ACC voxel, and the left DLPFC voxel, -because the left side of these brain regions are associated with the pathophysiology of depression 7)12) . The sizes of each ROI voxel was 1.5×1.5×1.5 cm 3 for the amygdala and DLPFC and 1.5×1.5×2.0 cm 3 for the ACC (Figure 1) . Voxel position for the left amygdala region comprised the maximum of amygdala gray matter and the anterior one-third of the hippocampus 7) . The ACC voxel abutted upon the anterior portion of the corpus callosum posteriorly. The caudate nucleus was well-formed visually at this level, but the sampling was near the superior portion of the putamen, at a level with dense striatal connections 11) . The superior frontal sulcus, lateral fissure, and genu of the corpus callosum were used as anatomical landmarks for placement of the DLPFC voxel 10) . Acquisition parameters were decided in accordance with prior studies, in which relatively accurate levels of Glx were obtained: echo time was 38 ms; and repetition time was 2.0 s.
Statistical analyses
Analysis of variance (ANOVA) based on parametric data and Tukey's honest significant difference (HSD) test -were used to compare Glx values in each brain region. A paired t-test was conducted for comparisons between groups. We used Pearson correlation coefficients to assess relation between Glx and severity in each region. All statistical tests were twotailed, and values of p < 0.05 were considered significant. EZR statistical software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) was used for all analyses.
Results
No significant differences were seen between the patient and control groups with regard to age or sex.
MRI results
In both the patient and control groups, some scans showed minor white matter hyperintensities, Abbreviatio :ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex HSD, honestly significant difference and some displayed increased cerebral spinal fluid spaces. These findings were attributable to physiologic age-related changes and were judged to be of no pathological significance. Some participants showed lacunar infarctions on the thalamus or basal ganglion, and small infarctions on white matter.
MRS results
In the patient group, Glx levels in the left amygdala, ACC and DLPFC were 15.0 ± 1.6, 12.3 ± 1.3, and 11.6 ± 1.3, respectively. The highest fitting error was 15 and the mean fitting error was 10.2. In the control group, Glx levels at the left amygdala, left ACC and left DLPFC were 16.0 ± 2.9, 12.5 ± 1.0, and 12.1 ± 1.3, respectively. The highest fitting error was 24, and the mean fitting error was 10.9. Among the three regions, the level of Glx was higher in the left amygdala than in the other regions [F(2, 33) = 18.4, p<0.05] ( Table 3) . Tukey HSD analysis confirmed the Glx value in left amygdala as the highest [p<0.05] ( Table 4) . Glx tended to be lower in the patient group than that in the control group in all three regions, but no significant difference between patients and controls was seen. No significant correlation was found between HAM-D scores and any regions of Glx using Pearson's correlation coefficient.
Discussion
This study investigated the most appropriate region for Glx measurement in patients with MDD. Glx was significantly higher in the amygdala than in the other two regions, and no differences were seen between patients and healthy controls. This might represent a physiological and characteristic distribution in MDD. The amygdala may be a suitable region for detecting neurotrophic effects by proton MRS 4)7) , as it is a highly neuroplastic active brain area 13) that fills the voxel mainly with grey matter 14) . The amygdala is a core component of the social brain and is critical to emotional expression, and not just for fear and anxiety 15)16) . Abnormal development of this structure is linked to the socio-emotional impairments of autism [16] [17] [18] and to the temporal course of depression and affective disorders [19] [20] [21] [22] . A high absolute value of Glx may be monitored in the amygdala in cases of autism or other affective disorders.
We found a tendency toward lower Glx in all three regions in the patient group compared to the control group, but no significant differences were seen between the three regions. One reason may be that the mean age of the participants was relatively higher compared with that of previous studies 5)8)12) . According to a recent study, Glx shows a decreasing trend with aging, because elderly individuals develop decreases in neuronal density and metabolic activity 23) . To investigate appropriate regions for measuring Glx in depression, we will need to examine a younger group. In addition, we could not clarify whether medications and treatments had affected the patient condition -because these were reported to increase or reverse Glx in previous studies 6) 7) . Patients in our study generally had severe depressive conditions and were receiving antidepressants before admission. A drug-induced effect regrading MRS has not been clearly shown, but it may be responsible for the findings in patients with MDD 24) , although previous studies 5)7) showed similar patient conditions. We also could not detect any correlations between symptom severity and concentration of Glx, consistent with previous MRS studies 5)8) . This lack of correlations might be one of the truths in real-world settings, but verification of this point is needed in the future.
Several limitations of this study require consideration. As with MRS examination, the optimal parameters might differ depending on the position or size of the ROI. However, in this study, parameters were set in the same manner regardless of such conditions. Second, the small number of subjects and lack of variety in the severity of MDD also limited our results, and were mainly attributed to difficulties in patient recruitment, although previous studies examined roughly equally sized groups. Third, Glx mostly represents the combined signal of glutamate and glutamine, with minor contributions from γamino butyric acid (GABA), aspartate, and other metabolites 3) . In particular, abnormalities of GABA are also well known in patients with MDD 8) . Undetected contributions from alterations in GABA levels therefore cannot be ruled out in our results. Despite these limitations, our study provides the first evidence of a physiologic and characteristic distribution of Glx in patients with MDD. Further MRS studies are needed to detect Glx for specific diagnoses and to evaluate severity and treatment effects in patients with MDD.
